Exelixis Inc Contract with Customer, Performance Obligation Satisfied in Previous Period
Exelixis Inc (EXEL) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $41.10 million for the 3-month period ending 2023-09-29, per its 10-Q filed 2023-11-01.
Discontinued › Notes › Revenue from Contract with Customer › Change in Contract with Customer, Asset and Liability
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2023-11-01
- Exelixis Inc contract with customer, performance obligation satisfied in previous period for the quarter ending 2023-09-29 was $41.10M, a 21.24% increase year-over-year.
- Exelixis Inc contract with customer, performance obligation satisfied in previous period for the quarter ending 2023-06-30 was $53.90M, a 9.26% decline year-over-year.
- Exelixis Inc contract with customer, performance obligation satisfied in previous period for the quarter ending 2023-03-31 was $37.90M, a 19.56% increase year-over-year.
- Exelixis Inc contract with customer, performance obligation satisfied in previous period for the quarter ending 2022-12-30 was $36.60M, a 12.62% increase year-over-year.
- Exelixis Inc contract with customer, performance obligation satisfied in previous period for fiscal 2022 was $161.60M, a 8.68% increase from fiscal 2021.
- Exelixis Inc contract with customer, performance obligation satisfied in previous period for fiscal 2021 was $148.70M, a 12.37% decline from fiscal 2021.
- Exelixis Inc contract with customer, performance obligation satisfied in previous period for fiscal 2021 was $169.70M, a 5.27% increase from fiscal 2020.
- Exelixis Inc contract with customer, performance obligation satisfied in previous period for fiscal 2020 was $161.20M, a 18.63% decline from fiscal 2018.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|
| 2023-09-29 | $41.10M 10-Q · filed 2023-11-01 | $95.00M derived: sum of 2 quarters · filed 2023-11-01 | $133.00M 10-Q · filed 2023-11-01 | $169.50M derived: sum of 4 quarters · filed 2023-11-01 |
| 2023-06-30 | $53.90M 10-Q · filed 2023-08-01 | $91.90M 10-Q · filed 2023-08-01 | $128.40M derived: sum of 3 quarters · filed 2023-08-01 | $162.30M derived: sum of 4 quarters · filed 2023-11-01 |
| 2023-03-31 | $37.90M 10-Q · filed 2023-05-09 | $74.50M derived: sum of 2 quarters · filed 2023-05-09 | $108.40M derived: sum of 3 quarters · filed 2023-11-01 | $167.80M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-12-30 | $36.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $70.50M derived: sum of 2 quarters · filed 2023-11-01 | $129.90M derived: sum of 3 quarters · filed 2023-11-01 | $161.60M 10-K · filed 2023-02-07 |
| 2022-09-30 | $33.90M 10-Q · filed 2023-11-01 | $93.30M derived: sum of 2 quarters · filed 2023-11-01 | $125.00M 10-Q · filed 2023-11-01 | $157.50M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-07-01 | $59.40M 10-Q · filed 2023-08-01 | $91.10M 10-Q · filed 2023-08-01 | $123.60M derived: sum of 3 quarters · filed 2023-08-01 | $172.00M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-04-01 | $31.70M 10-Q · filed 2023-05-09 | $64.20M derived: sum of 2 quarters · filed 2023-05-09 | $112.60M derived: sum of 3 quarters · filed 2023-05-09 | $153.20M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $32.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $80.90M derived: sum of 2 quarters · filed 2023-02-07 | $121.50M derived: sum of 3 quarters · filed 2023-02-07 | $148.70M 10-K · filed 2023-02-07 |
| 2021-10-01 | $48.40M 10-Q · filed 2022-11-01 | $89.00M derived: sum of 2 quarters · filed 2022-11-01 | $116.20M 10-Q · filed 2022-11-01 | $171.20M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | $40.60M 10-Q · filed 2021-08-05 | $67.80M 10-Q · filed 2021-08-05 | $122.80M derived: sum of 3 quarters · filed 2023-02-07 | $155.90M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $27.80M 10-Q · filed 2022-05-10 | $82.20M derived: sum of 2 quarters · filed 2023-02-07 | $115.30M derived: sum of 3 quarters · filed 2023-02-07 | $177.30M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | $54.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $87.50M derived: sum of 2 quarters · filed 2023-02-07 | $149.50M derived: sum of 3 quarters · filed 2023-02-07 | $169.70M 10-K · filed 2023-02-07 |
| 2020-10-02 | $33.10M 10-Q · filed 2021-11-02 | $95.10M derived: sum of 2 quarters · filed 2021-11-02 | $115.30M 10-Q · filed 2021-11-02 | $146.10M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $62.00M 10-Q · filed 2021-08-05 | $82.20M 10-Q · filed 2021-08-05 | $113.00M derived: sum of 3 quarters · filed 2022-02-18 | $180.70M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $18.80M 10-Q · filed 2021-05-06 | $51.00M derived: sum of 2 quarters · filed 2022-02-18 | $118.70M derived: sum of 3 quarters · filed 2022-02-18 | $154.80M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | $32.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $99.90M derived: sum of 2 quarters · filed 2022-02-18 | $136.00M derived: sum of 3 quarters · filed 2022-02-18 | $161.20M 10-K · filed 2022-02-18 |
| 2019-09-27 | $67.70M 10-Q · filed 2020-11-05 | $103.80M derived: sum of 2 quarters · filed 2020-11-05 | $129.00M 10-Q · filed 2020-11-05 | $175.40M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-28 | $36.10M 10-Q · filed 2020-08-06 | $61.40M 10-Q · filed 2020-08-06 | $107.70M derived: sum of 3 quarters · filed 2020-08-06 | $155.90M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-29 | $25.30M 10-Q · filed 2020-05-05 | $71.60M derived: sum of 2 quarters · filed 2020-05-05 | $119.80M derived: sum of 3 quarters · filed 2020-05-05 | $152.00M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-28 | $46.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $94.50M derived: sum of 2 quarters · filed 2019-10-30 | $126.70M derived: sum of 3 quarters · filed 2019-10-30 | $198.10M 10-K · filed 2021-02-11 |
| 2018-09-28 | $48.20M 10-Q · filed 2019-10-30 | $80.40M derived: sum of 2 quarters · filed 2019-10-30 | $151.80M 10-Q · filed 2019-10-30 | |
| 2018-06-29 | $32.20M 10-Q · filed 2019-07-31 | $103.80M 10-Q · filed 2019-07-31 | ||
| 2018-03-31 | $71.30M 10-Q · filed 2018-05-02 | |||
| 2018-03-30 | $71.30M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |